title: Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial.
abstract: OBJECTIVE
  Hyperglycemia is associated with worse outcome in patients with acute stroke.
  
  
  METHODS
  We conducted a prospective, randomized, multicenter, 3-arm trial (tight control [target 70 to 110 mg/dL], loose control [target 70 to 200 mg/dL], and control usual care [70 to 300 mg/dL]) to assess the feasibility and safety of 2 insulin infusion protocol targets in patients with acute ischemic stroke. The planned sample was 72 subjects.
  
  
  RESULTS
  A total of 74 subjects were enrolled. Seventy-two (97%) had data available for the primary analyses and 73 (99%) had 3-month clinical outcome data. Median age was 67 years, median National Institutes of Health Stroke Scale score was 8, median glucose was 163 mg/dL, and median time to randomization was 10.7 hours. Fifty-nine percent of patients were diabetic, 35% received thrombolysis, and 14% of subjects died within 3 months. The loose control and usual care groups had median glucose concentrations of 151 mg/dL. The tight control group had a median glucose concentration of 111 mg/dL. The loose control group spent 90% of the first 24 hours in target and the tight group 44% of time in target. There was only one symptomatic patient with hypoglycemia in the loose control group (4%) and zero in the tight control group. The overall rates of hypoglycemia (<55 mg/dL) were 4% in control, 4% in loose, and 30% in tight. Exploratory efficacy analysis was conducted.
  
  
  CONCLUSIONS
  Insulin infusion for patients with acute ischemic stroke is feasible and safe using the insulin infusion protocol in the Glucose Regulation in Acute Stroke Patients (GRASP) trial. Exploratory efficacy analysis supports further comparative study.
authors.affiliation: Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, VA 22908, USA. Kj4v@virginia.edu
authors.forename: Karen C
authors.initials: KC
authors.lastname: Johnston
authors.forename: Christiana E
authors.initials: CE
authors.lastname: Hall
authors.forename: Brett M
authors.initials: BM
authors.lastname: Kissela
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Bleck
authors.forename: Mark R
authors.initials: MR
authors.lastname: Conaway
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D020521:Stroke / Q000378:metabolism* / Q000401:mortality
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin